Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Lindis Biotech GmbH, corporate

Lindis Biotech GmbH,

13.04.2021 - 10:03:40

LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer

lindis-biotech@mc-services.eu ? ? ?

13.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Lindis Biotech GmbH Am Klopferspitz 19 82152 Martinsried

Germany Phone: +4989200066440 E-mail: info@lindisbiotech.de Internet: https://www.lindisbiotech.com/ EQS News ID: 1183709 ? End of News DGAP News Service


@ dgap.de